Alliance for Pandemic Preparedness
October 23, 2020
Tocilizumab in Nonventilated Patients Hospitalized with Covid-19 Pneumonia
Category: Article Summary
Topic: Testing and Treatment
Keywords (Tags): treatment
- [Pre-print, not peer-reviewed] The randomized, placebo-controlled multi-country EMPACTA trial indicated that tocilizumab reduced the likelihood of progression to requiring mechanical ventilation or death in patients who were hospitalized with COVID-19 pneumonia and were not on a ventilator (n=389). The cumulative proportion of patients requiring mechanical ventilation or who had died by day 28 was 12% in the tocilizumab group and 19% in the placebo groups (HR=0.56, 95%CI 0.33 – 0.97). All-cause mortality by Day 28 was 10% with tocilizumab and 9% with placebo. Serious adverse events occurred in 15% of patients receiving tocilizumab and 20% of patients receiving placebo.
Salama et al. (Oct 23, 2020). Tocilizumab in Nonventilated Patients Hospitalized with Covid-19 Pneumonia. Pre-print downloaded Oct 23 from https://doi.org/10.1101/2020.10.21.20210203